FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157202113> ?p ?o ?g. }

• W3157202113 endingPage "1924" @default.
• W3157202113 startingPage "1916" @default.
• W3157202113 abstract "Abstract Background Perinatal human immunodeficiency virus type 1 (HIV-1) continues to occur due to barriers to effective antiretroviral prevention that might be mitigated by long-acting broadly neutralizing monoclonal antibodies (bNAbs). Methods An extended half-life bNAb, VRC01LS, was administered subcutaneously at 80 mg/dose after birth to HIV-1–exposed, nonbreastfed (cohort 1, n = 10) and breastfed (cohort 2, n = 11) infants. Cohort 2 received a second dose (100 mg) at 12 weeks. All received antiretroviral prophylaxis. VRC01LS levels were compared to VRC01 levels determined in a prior cohort. Results Local reactions (all grade ≤2) occurred in 67% and 20% after dose 1 and dose 2, respectively. The weight-banded dose (mean 28.8 mg/kg) of VRC01LS administered subcutaneously achieved a mean (standard deviation) plasma level of 222.3 (71.6) µg/mL by 24 hours and 44.0 (11.6) µg/mL at week 12, prior to dose 2. The preestablished target of ≥50 µg/mL was attained in 95% and 32% at weeks 8 and 12, respectively. The terminal half-life was 37–41 days. VRC01LS level after 1 dose was significantly greater (P &lt;.002) than after a VRC01 dose (20 mg/kg). No infants acquired HIV-1. Conclusions VRC01LS was well tolerated with pharmacokinetics that support further studies of more potent long-acting bNAbs as adjunct treatment with antiretrovirals to prevent infant HIV-1 transmission." @default.
• W3157202113 created "2021-05-10" @default.
• W3157202113 creator A5010772046 @default.
• W3157202113 creator A5018055017 @default.
• W3157202113 creator A5021608465 @default.
• W3157202113 creator A5026928748 @default.
• W3157202113 creator A5032921214 @default.
• W3157202113 creator A5037205982 @default.
• W3157202113 creator A5040076878 @default.
• W3157202113 creator A5043215854 @default.
• W3157202113 creator A5046208449 @default.
• W3157202113 creator A5048622777 @default.
• W3157202113 creator A5049003583 @default.
• W3157202113 creator A5052819133 @default.
• W3157202113 creator A5059245006 @default.
• W3157202113 creator A5071657202 @default.
• W3157202113 creator A5072695367 @default.
• W3157202113 creator A5077024538 @default.
• W3157202113 creator A5077436590 @default.
• W3157202113 creator A5084890323 @default.
• W3157202113 creator A5086606150 @default.
• W3157202113 creator A5088599901 @default.
• W3157202113 creator A5089495152 @default.
• W3157202113 creator A5089668777 @default.
• W3157202113 date "2021-05-02" @default.
• W3157202113 modified "2023-10-16" @default.
• W3157202113 title "Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1–Exposed Newborn Infants" @default.
• W3157202113 cites W1924338894 @default.
• W3157202113 cites W1974431423 @default.
• W3157202113 cites W1992566288 @default.
• W3157202113 cites W2046849676 @default.
• W3157202113 cites W2061691913 @default.
• W3157202113 cites W2071843728 @default.
• W3157202113 cites W2098013141 @default.
• W3157202113 cites W2108422942 @default.
• W3157202113 cites W2113236498 @default.
• W3157202113 cites W2118274231 @default.
• W3157202113 cites W2125143554 @default.
• W3157202113 cites W2135151522 @default.
• W3157202113 cites W2157450041 @default.
• W3157202113 cites W2200798239 @default.
• W3157202113 cites W2294858472 @default.
• W3157202113 cites W2308542537 @default.
• W3157202113 cites W2551273870 @default.
• W3157202113 cites W2617945291 @default.
• W3157202113 cites W2768623425 @default.
• W3157202113 cites W2775984892 @default.
• W3157202113 cites W2785308733 @default.
• W3157202113 cites W2811454587 @default.
• W3157202113 cites W2897595682 @default.
• W3157202113 cites W2900872216 @default.
• W3157202113 cites W2969038446 @default.
• W3157202113 cites W2972434296 @default.
• W3157202113 cites W2984342233 @default.
• W3157202113 cites W2986455612 @default.
• W3157202113 cites W2998970731 @default.
• W3157202113 cites W2999692731 @default.
• W3157202113 cites W3008301033 @default.
• W3157202113 cites W3033554563 @default.
• W3157202113 cites W3047278933 @default.
• W3157202113 cites W3049240211 @default.
• W3157202113 cites W3082871876 @default.
• W3157202113 cites W3093221995 @default.
• W3157202113 cites W3138052084 @default.
• W3157202113 cites W3138945586 @default.
• W3157202113 doi "https://doi.org/10.1093/infdis/jiab229" @default.
• W3157202113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34009371" @default.
• W3157202113 hasPublicationYear "2021" @default.
• W3157202113 type Work @default.
• W3157202113 sameAs 3157202113 @default.
• W3157202113 citedByCount "21" @default.
• W3157202113 countsByYear W31572021132021 @default.
• W3157202113 countsByYear W31572021132022 @default.
• W3157202113 countsByYear W31572021132023 @default.
• W3157202113 crossrefType "journal-article" @default.
• W3157202113 hasAuthorship W3157202113A5010772046 @default.
• W3157202113 hasAuthorship W3157202113A5018055017 @default.
• W3157202113 hasAuthorship W3157202113A5021608465 @default.
• W3157202113 hasAuthorship W3157202113A5026928748 @default.
• W3157202113 hasAuthorship W3157202113A5032921214 @default.
• W3157202113 hasAuthorship W3157202113A5037205982 @default.
• W3157202113 hasAuthorship W3157202113A5040076878 @default.
• W3157202113 hasAuthorship W3157202113A5043215854 @default.
• W3157202113 hasAuthorship W3157202113A5046208449 @default.
• W3157202113 hasAuthorship W3157202113A5048622777 @default.
• W3157202113 hasAuthorship W3157202113A5049003583 @default.
• W3157202113 hasAuthorship W3157202113A5052819133 @default.
• W3157202113 hasAuthorship W3157202113A5059245006 @default.
• W3157202113 hasAuthorship W3157202113A5071657202 @default.
• W3157202113 hasAuthorship W3157202113A5072695367 @default.
• W3157202113 hasAuthorship W3157202113A5077024538 @default.
• W3157202113 hasAuthorship W3157202113A5077436590 @default.
• W3157202113 hasAuthorship W3157202113A5084890323 @default.
• W3157202113 hasAuthorship W3157202113A5086606150 @default.
• W3157202113 hasAuthorship W3157202113A5088599901 @default.
• W3157202113 hasAuthorship W3157202113A5089495152 @default.
• W3157202113 hasAuthorship W3157202113A5089668777 @default.
• W3157202113 hasBestOaLocation W31572021132 @default.

• next